CSBio CSBio

X
[{"orgOrder":0,"company":"WuXi Biologics","sponsor":"AC Immune","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AC Immune and WuXi Biologics Strengthen Strategic Partnership to Accelerate AC Immune\u2019s Anti-TDP-43 Antibodies into Clinical Development","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"WuXi Biologics"},{"orgOrder":0,"company":"Creative Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Creative Medical Technology Holdings Identifies Mechanism of Action of ImmCelz\u00ae Stroke Regenerative Activity","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Creative Medical"},{"orgOrder":0,"company":"Bened Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Psychobiotic PS128 Consumption Shows Benefits to Parkinson's Symptoms in New Clinical Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Bened Biomedical"},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akeso's NGF Monoclonal Antibody (AK115) Approved To Initiate Clinical Trial In Pain (Including Cancer Pain)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Akeso"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ractigen Therapeutics Receives FDA Orphan Drug Designation For the Novel Oligonucleotide Conjugate RAG-17 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Ractigen Therapeutics"},{"orgOrder":0,"company":"Hangzhou Highlightll Pharmaceutical","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","amount":"$970.0 million","upfrontCash":"$10.0 million","newsHeadline":"Biohaven Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2\/JAK1 Inhibitor for Immune-Mediated Brain Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Hangzhou Highlightll Pharmaceutical"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"University Medical Center Utrecht","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ractigen Therapeutics Enters Strategic Partnership with University Medical Center Utrecht to Drive saRNA Innovation in Neurodevelopmental Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Large molecule","graph2":"Ractigen Therapeutics"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            This strategic alliance unites their respective strengths to advance the development of saRNA-based treatments for a spectrum of intractable neurodevelopmental disorders.

            Lead Product(s): saRNA-based Therapy

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: University Medical Center Utrecht

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership January 29, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreement, Biohaven and Highlightll will coordinate clinical development across global regions for BHV-8000 (previously TLL-041), an oral, brain-penetrant, dual inhibitor of TYK2 and JAK1 for the treatment of brain disorders.

            Lead Product(s): BHV-8000

            Therapeutic Area: Neurology Product Name: BHV-8000

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Biohaven Pharmaceuticals

            Deal Size: $970.0 million Upfront Cash: $10.0 million

            Deal Type: Licensing Agreement March 22, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            RAG-17 is a therapeutic siRNA designed to target and knockdown the expression of SOD1 gene in patients with pathogenic mutations known to cause amyotrophic lateral sclerosi.

            Lead Product(s): RAG-17

            Therapeutic Area: Neurology Product Name: RAG-17

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 03, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            AK115 (NGF monoclonal antibody), with the characteristics of long-term safety and non-addictive, will give priority to the evaluation of safety and efficacy in advanced cancer patients, which is expected to bring hope to opioid-resistant advanced cancer patients.

            Lead Product(s): AK115

            Therapeutic Area: Neurology Product Name: AK115

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 10, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Bened Biomedical, a leading Taiwanese probiotic company, has announced a successful clinical study for its PS128 psychobiotic in treating symptoms of Parkinson's disease (PD). The study was led by a neurologist, Dr. Chin-Song Lu, a renowned researcher for PD in Taiwan.

            Lead Product(s): Lactobacillus Plantarum

            Therapeutic Area: Neurology Product Name: PS128

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 18, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The Company reported that animals having previously been treated with ImmCelz® have an increase in what is called "endogenous neurogenesis".

            Lead Product(s): ImmCelz

            Therapeutic Area: Neurology Product Name: ImmCelz

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 22, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The partnership focuses on developing AC Immune’s clinical antibody candidate to ensure it has high-affinity for TDP-43 and is capable of preventing the intercellular spread of toxic species.

            Lead Product(s): Anti-TDP-43 antibody

            Therapeutic Area: Neurology Product Name: Anti-TDP-43 antibody

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: AC Immune

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership November 09, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY